Benralizumab for Severe Asthma with Aspergillus Allergy
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with severe asthma that has required high-dose inhaled steroid medications plus at least one other asthma controller for at least 3 months
- At least 2 asthma flare-ups in the past 12 months that needed oral or injected steroids
- Blood tests showing allergy to Aspergillus mold (either a skin test or elevated antibody levels) and total IgE (allergy marker) above 1,000 IU/mL
- Weigh more than 40 kg (about 88 pounds)
- Not a current smoker and no smoking history of more than 10 pack-years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug tezepelumab works in treating allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergic reaction to a common fungus. It may help reduce asthma symptoms and flare-ups in people with severe asthma related to ABPA.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
This study tests a new way to take asthma medicine using a device that tracks your inhaler use. If you already use Fasenra (benralizumab) for severe asthma, you may be able to join.
This study looks at people with allergic bronchopulmonary aspergillosis (ABPA), a lung condition caused by an allergy to a common mold. It helps doctors learn more about the disease so they can improve care for future patients.
Hear when a new Allergic Bronchopulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.